These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1369591)

  • 1. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats.
    Pinski J; Yano T; Schally AV
    Neuroendocrinology; 1992 Dec; 56(6):831-7. PubMed ID: 1369591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
    Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
    Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
    Pinski J; Yano T; Rekasi Z; Cai RZ; Radulovic S; Schally AV
    Regul Pept; 1992 Oct; 41(3):185-93. PubMed ID: 1438988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intracerebral ventricular administration of gastrin-releasing peptide and its receptor antagonist RC-3095 on learned fear responses in the rat.
    Merali Z; Mountney C; Kent P; Anisman H
    Behav Brain Res; 2011 Jan; 216(2):519-24. PubMed ID: 20801162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the gonadotropin-releasing hormone associated peptides (GAP) on the release of luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin (PRL) in vivo.
    Yu WH; Arisawa M; Millar RP; McCann SM
    Peptides; 1989; 10(6):1133-8. PubMed ID: 2516311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal luteinizing hormone and follicle-stimulating hormone release rates as a function of time after castration in female and male rats.
    Olson DR; Blake CA
    Neuroendocrinology; 1991 Feb; 53(2):124-33. PubMed ID: 1901631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen inhibits luteinizing hormone (LH), but not follicle-stimulating hormone secretion in hypophysectomized pituitary-grafted rats receiving pulsatile LH-releasing hormone infusions.
    Strobl FJ; Levine JE
    Endocrinology; 1988 Jul; 123(1):622-30. PubMed ID: 3133202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
    Szepeshazi K; Schally AV; Halmos G; Lamharzi N; Groot K; Horvath JE
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10913-8. PubMed ID: 9380734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.